(NASDAQ: PTCT) Ptc Therapeutics's forecast annual revenue growth rate of -4.62% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.95%.
Ptc Therapeutics's revenue in 2024 is $927,558,000.On average, 6 Wall Street analysts forecast PTCT's revenue for 2024 to be $52,421,485,580, with the lowest PTCT revenue forecast at $41,331,897,437, and the highest PTCT revenue forecast at $64,839,462,039. On average, 6 Wall Street analysts forecast PTCT's revenue for 2025 to be $50,490,797,411, with the lowest PTCT revenue forecast at $26,820,865,715, and the highest PTCT revenue forecast at $64,663,059,434.
In 2026, PTCT is forecast to generate $64,893,763,363 in revenue, with the lowest revenue forecast at $41,914,793,003 and the highest revenue forecast at $89,804,265,557.